Safety and Efficacy of Combined Ruxolitinib and Decitabine in Accelerated and Blast-Phase Myeloproliferative Neoplasms

This phase 1 trial analyzed ruxolitinib plus decitabine in patients with accelerated or blast-phase myeloproliferative neoplasms. Its results suggest that the combination in generally well tolerated and shows potential promising efficacy for a patient population that has thus far had limited treatment options.

Blood Advances